NASDAQ : NRXP
NRx Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.66 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 115.08M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 98.21M |
| Enterprise Value | 72.35M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 43.26M |
| Shares Outstanding | 43.26M |
| Shares Change (YoY) | +110.42% |
| Shares Change (QoQ) | +16.47% |
| Owned by Insiders (%) | 4.12% |
| Owned by Institutions (%) | 21.87% |
| Float | 37.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 28.94 |
| Forward PS | 2.68 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 21.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.86 |
| Quick Ratio | 0.79 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.50 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -63.99% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -6,980.42% |
| Weighted Average Cost of Capital (WACC) | 16.43% |
| Revenue Per Employee | $117,034 |
| Profits Per Employee | -$809,655 |
| Employee Count | 29 |
| Asset Turnover | 0.17 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.07 |
| 52-Week Price Change | -25.57% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 2.97 |
| Relative Strength Index (RSI) | 29.90 |
| Average Volume (20 Days) | 1,543,124 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.95M |
| Short Previous Month | 9.79M |
| Short % of Shares Out | 23.00% |
| Short % of Float | 26.61% |
| Short Ratio (days to cover) | 14.64 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.39M |
| Gross Profit | 1.58M |
| Operating Income | -19.96M |
| Pretax Income | -23.48M |
| Net Income | -23.48M |
| EBITDA | -19.76M |
| EBIT | -19.96M |
| Loss Per Share | -$0.78 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 26.69M |
| Total Debt | 834,000 |
| Net Cash | 25.85M |
| Net Cash Per Share | $0.60 |
| Equity (Book Value) | -170,000 |
| Book Value Per Share | -0.00 |
| Working Capital | -4.72M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -19.77M |
| Capital Expenditures | -897,000 |
| Depreciation & Amortization | 202,000 |
| Net Borrowing | 33,000 |
| Free Cash Flow | -20.67M |
| FCF Per Share | -$0.48 |
Margins
| Measure | Value |
|---|
| Gross Margin | 46.64% |
| Operating Margin | -588.21% |
| Pretax Margin | -691.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -110.42% |
| Shareholder Yield | -110.42% |
| Earnings Yield | -34.16% |
| FCF Yield | -21.05% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $38.50 |
| Price Target Difference | 1,596.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 668.69% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Apr 2, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -13.93 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |